All News

The Aplastic Anemia & MDS International Foundation presented its first Lifetime Achievement in Science Award to Mary Horowitz, MD, MS at the Foundation’s 35th Anniversary Luncheon and Awards Program on May 18, 2019. Dr. Horowitz was honored for the significant impact her work has had on stem cell transplant and hematologic malignancy practice worldwide.

Increased tumor mutation burden (TMB), which is associated with more inflammation, may be a factor in determining which patients with lung cancer are at higher risk for depression.

In the second part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him about the past, present and future of the myeloma landscape.

In this essay, Honora R. Miller nominates a special oncology nurse practitioner, Joanna M. Losito, Sutter Health Palo Alto Medical Foundation–Sunnyvale Center, Sunnyvale, California, for CURE®’s 2019 Extraordinary Healer® Award.

Cancer is a huge, life-changing event for a family and the power of the experience in a young person’s life should not be underestimated. What is a semester at college compared to the learning and self-understanding that comes from being with your family in such a stressful time?

Breast cancer survivorship is something to celebrate and there are many ways to commemorate the fact, but are t-shirts and other items the best way to honor survivors? One survivor shares her perspective and reflects on National Cancer Survivor’s Day.

When I was diagnosed with Hodgkin's lymphoma, I envisioned myself in a galaxy far, far away. Just like any well-trained Jedi, I fought back when insurance denied my claim for doctor-recommended treatment.

From cancer-sniffing dogs to music therapy for pain, here’s what is making headlines in the cancer space this week.

The growing use of immunotherapy in oncology has confronted many community practice-based oncologists with challenges to implementation, but one advocacy group’s new initiative aims to educate and empower.

I have a daily calendar on my desk with very wise sayings. One that really stood out was by J.C.Watts. “It doesn’t take a lot of strength to hang on. It takes a lot of strength to let go.”

Many survivors face times of worry and anxiety. An upcoming appointment, a scan, a new lump, bump or spot can all be triggers for feeling intense anxiety. Here are three simple tools from a fellow survivor to help cope in those times.

In the first part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him on the current initiatives and resources available to patients.

Routine use of prophylactic radiotherapy in patients with malignant pleural mesothelioma is unnecessary following a chest wall procedure, according to multicenter, open-label, phase 3, randomized controlled trial findings published in the Journal of Clinical Oncology.

What a force they were, those two daughters of ours: that little nine-year-old kid Valerie, gone from bone cancer and the more grown-up 37-year-old Stacy, cut off by breast cancer. When we talk of them, however, it is often with a slight grin.

Mindfulness and meditation for the masses. What does this mean to those of us with a life-threatening disease?

The financial navigation program at Taussig Cancer Institute provides patient assistance and helps them understand out-of-pocket costs.

Even a cancer survivor with an upbeat attitude can experience bittersweet blues sometimes out of the blue. There are ways to learn from this feeling, whatever we call it, and keep on going.

Results from a clinical trial in people with mesothelioma indicate that an experimental chimeric antigen receptor-T cell therapy is safe and may provide benefit to patients, especially in combination with other immunotherapies.

Can fitness make you physically prepared for a medical detour?

Patients with chronic lymphocytic leukemia should learn about the latest advancements, says one expert.

The Food and Drug Administration approved Keytruda for the treatment of patients with metastatic small cell lung cancer.

Maintenance therapy with defactinib failed to improve survival following front-line chemotherapy in patients with merlin-low malignant pleural mesothelioma, according to results from the phase 2 COMMAND trial.

A novel imaging test developed at UT Southwestern may help to determine which patients with kidney cancer would benefit from treatment with immunotherapy.

When my oncologist wanted to start me on a standard treatment, I asked her why. She said some of her other patients had gotten it. She was basing my life on someone else’s results? This survivor decided to seek other opinions and became her own advocate.

Getting back up matters when cancer knocks you down, but so does pausing for reflection.

Autoimmune skin toxicities in patients with non-small cell lung cancer mean patients may respond better to immune checkpoint inhibitors.

As a cancer survivor, I am always on my toes.

Should patients be given a choice on how they wish to receive bad news? One survivor seems to think so.

While advances have been made in the treatment landscape of hepatocellular carcinoma, researchers are now looking into the optimal sequence for which patients should be treated.

From the 9/11 Victim Compensation Fund to the untimely passing of an inspirational Olympic runner, here’s what is making headlines in the cancer space this week.